AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 32 min read$MDGL

Madrigal: Q3 Earnings Snapshot

Madrigal Pharmaceuticals (MDGL) reported Q3 earnings of $55.4M, or $1.83 per share, exceeding analyst expectations of a $1.09 per share loss. Revenue was $431.3M, surpassing the $400M forecast.

Original reporting
finance.yahoo.com
Published Nov 3, 2026, 12:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 12:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Madrigal: Q3 Earnings Snapshot — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$MDGLBullishMed
01

Why it matters

The explicit EPS and revenue beats are the main tradable information, but the lack of guidance or additional catalysts limits decision-making beyond the immediate earnings reaction.

02

Market read

Traders can update positions based on the reported Q3 EPS and revenue beats versus consensus, but should verify any guidance in the full filing.

03

What to watch

No forward guidance, cash flow detail, or pipeline/trial updates are included, so traders may need the full earnings release to assess follow-through.

Relevance 8/10Novelty 8/10Timing: reported Tuesday, during the earnings window

Background

The article is an AP earnings snapshot generated from Zacks data, reporting Q3 EPS and revenue versus analyst expectations.

Company-level read

Ticker impact

$MDGLBullishMedium confidence
Context

Madrigal Pharmaceuticals reported Q3 profit of $1.83 per share and revenue of $431.3 million, both topping analyst expectations.

Expected impact

Likely upward bias as the market digests the earnings beat versus consensus.

Evidence & confidence

The piece is a first-report earnings snapshot with explicit beat figures versus Zacks estimates, but lacks forward-looking guidance or additional material developments.

Market effects

Sector

Biopharma earnings prints can modestly influence sentiment toward small/mid-cap biotech profitability, but no sector-wide signal is provided here.

Regional

Limited, company-specific impact with no broader regional macro or supply-chain linkage mentioned.

Global

Low, as the article contains no international regulatory, trial, or commercialization developments.

Counterpoint

What could challenge this read

A headline beat may not sustain if investors focus on durability of margins or pipeline risk, which are not discussed in this snapshot.

Key entities

  • company
    Madrigal Pharmaceuticals Inc.

    US-listed biopharmaceutical company reporting Q3 earnings results.

  • source
    Zacks Investment Research

    Cited analyst consensus estimates used for the beat/miss comparison.

Read at source← All news

StoryMadrigal Pharmaceuticals posts Q3 2026 earnings beat, shares jump double‑digits

Also covered by

4 outlets

Related articles

NOV 3
$MDGLMed

Madrigal Swings To Q3 Profit As Rezdiffra Sales Jump 50%

Madrigal Pharmaceuticals (MDGL) reported a Q3 profit of $55.44M, reversing a year-earlier loss, driven by a 50% sales increase of Rezdiffra to $431.30M. R&D expenses declined, while SG&A and cost of sales rose. Over 55,850 patients are now using Rezdiffra, and the company plans a Phase 3 trial for MASH cirrhosis in 2027. MDGL stock is up 9.89%.

rttnews.com2 min
NOV 3
$MDGLHigh

Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates

MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates • Third-quarter 2026 Rezdiffra ® (resmetirom) net sales of $431.3 million, representing year-over-year growth of 50%; achieved first quarter of profitability • Rezdif

SEC EDGAR 8-K3 min
NOV 3
$MDGLHighAI 9/10

Why is Madrigal Pharmaceuticals stock surging today?

Madrigal Pharmaceuticals stock surged 14.1% to $491.90 after Q3 2026 results beat expectations, with adjusted earnings of $1.83 per share and revenue of $431.3 million. Rezdiffra, the company's flagship drug, drove revenue growth and achieved blockbuster status. CEO Bill Sibold highlighted continued demand and market growth. The company also announced a new clinical trial. Analysts had a positive outlook before the report.

investing.com2 min